Harber Asset Management’s AbbVie ABBV Stock Holding History

Harber Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-732	Closed	-$822K	–	41
2019 Q3	$822K	Buy	+732	New	+$50.2K	0.23%	37

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Harber Asset Management's ABBV Position: Q1 2020 in Review

Harber Asset Management sold out of AbbVie (ABBV) in Q1 2020, closing a stake of 30,652 shares — an estimated $2.61M sold.

Harber Asset Management first reported a position in ABBV in Q3 2019 and held it in 2 quarters. The position peaked at $2.71M in Q4 2019. 2,225 funds tracked by Wall St. Rank hold ABBV as of Q1 2020.

Harber Asset Management reported no remaining AbbVie position as of Q1 2020 after selling out during the quarter.
Harber Asset Management sold 30,652 AbbVie shares in Q1 2020, an estimated $2.61M.
Harber Asset Management first reported a position in AbbVie in Q3 2019 and held it in 2 quarters.
Harber Asset Management's AbbVie position peaked at $2.71M in Q4 2019.
2,225 funds tracked by Wall St. Rank held AbbVie as of Q1 2020.

Based on Harber Asset Management's 13F filing for Q1 2020, filed 15 May 2020.